Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor

• Main Authors: Bajars, M. (Author), Bennouna, J. (Author), Goel, S. (Author), Gulley, J.L (Author), Hrinczenko, B. (Author), Iannotti, N. (Author), Kelly, K. (Author), Manitz, J. (Author), Ruisi, M. (Author), Safran, H. (Author), Spigel, D. (Author), Taylor, M.H (Author), Verschraegen, C. (Author), Wong, D.J (Author)
• Format: Article
• Language: English
• Published: Future Medicine Ltd. 2022
• Subjects: Antibodies, Monoclonal, Humanized; avelumab; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical trials; disease exacerbation; Disease Progression; human; Humans; Immunotherapy; Lung; Lung Neoplasms; lung tumor; Metastasis; monoclonal antibody; non small cell lung cancer; pathology; programmed death 1 ligand 1; Solid tumors
• Online Access: View Fulltext in Publisher

 Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Results: Individuals with varying baseline characteristics who had received up to 6 years of avelumab were reviewed. Overall, 37/340 (10.9%) had received ≥2 years of treatment; in this subgroup, best response was complete response in 5.4%, partial response in 59.5% and stable disease in 29.7%; 51.4% had continued treatment beyond disease progression. Conclusions: In this study, 11% of patients with advanced non-small-cell lung cancer received ≥2 years of avelumab treatment and experienced prolonged response or continued clinical benefit. © 2022 The Authors.